17-P for Women With Congenital Uterine Anomalies: Does it Impact Preterm Birth Risk? [01K

Abstract

INTRODUCTION: The effectiveness of 17P in the prevention recurrent of preterm birth (PTB) among women with congenital uterine anomalies (CUA) is unknown. This study evaluate association between 17P and delivery gestational age among women with CUA and a previous spontaneous PTB. METHODS: This study is a retrospective cohort of women with CUA who delivered at 2 health systems from 2013-2019. Women with ≥1 prior spontaneous PTB carrying non-anomalous, singleton gestations were included. The primary outcome was delivery gestational age. Secondary outcomes included delivery <37 and <34 weeks. Women receiving 17P were compared to those who did not receive 17P using Wilcoxon rank sum, Fisher’s exact, and chi-square. RESULTS: Of the 48 women with prior PTB, 11 (22.9%) received 17P. Demographic, medical, and obstetric characteristics were similar between women who did and did not get 17P. The subtype of CUA was also similar by 17P status. The initial cervical length was more than 35mm in both groups and did not differ, nor did rates of PPROM (25% vs 12.5%, 0.63). The median delivery gestational age was similar between groups [37.7 (IQR 30.7-38.3) vs. 37.1 (IQR 31-38.4) weeks] for those who did and did not receive 17P, respectively. Rates of recurrent PTB 0.99) and 0.99) were also similar in those who did and did not receive 17P. CONCLUSION: In this cohort of women with prior PTB and CUA, recurrent PTB was common, and though 17P was used in fewer than 1 in 4 women, use of 17P did not appear to impact this risk.